Physician profile
Mansoor Khalid
NPI 1700078797
$1,118.84
in general payments reported to CMS, 2019-2025
18 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2022: $275 · 2024: $239 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644 · Education: $31.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.47 |
| Education | $31.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $218.95 | 2022-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $205.13 | 2025 | Terlivaz |
| Amgen INC. | $129.74 | 2024-2025 | Krystexxa, Tavneos |
| Vifor Pharma, INC. | $119.69 | 2019 | |
| Novo Nordisk INC | $117.25 | 2022 | |
| Novartis Pharmaceuticals Corporation | $65.38 | 2022-2025 | |
| Recor Medical INC | $44.98 | 2024 | Paradise Renal Denervation System |
| Opko Pharmaceuticals, LLC | $35.29 | 2024 | Rayaldee |
| Fresenius USA Marketing, INC. | $24.10 | 2025 | Velphoro |
| Pharmacosmos Therapeutics INC. | $21.84 | 2025 | Monoferric |
| Aurinia Pharma U.S., INC. | $21.84 | 2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.31 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.93 | 2024 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $17.71 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.62 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $15.12 | 2025 | Benlysta |
| Pfizer INC. | $15.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mansoor Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.